US5602024A
(en)
|
1994-12-02 |
1997-02-11 |
Synaptic Pharmaceutical Corporation |
DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
|
US5989920A
(en)
|
1994-12-02 |
1999-11-23 |
Synaptic Pharmaceutical Corporation |
Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
|
EP1007073A4
(en)
*
|
1996-06-04 |
2002-03-27 |
Synaptic Pharma Corp |
Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
|
US6713265B1
(en)
|
1997-06-04 |
2004-03-30 |
Synaptic Pharmaceutical Corporation |
Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
|
AU1262199A
(en)
*
|
1997-11-28 |
1999-06-16 |
Banyu Pharmaceutical Co., Ltd. |
Antihyperlipemic agents
|
US6187777B1
(en)
|
1998-02-06 |
2001-02-13 |
Amgen Inc. |
Compounds and methods which modulate feeding behavior and related diseases
|
JP2000119271A
(en)
|
1998-08-12 |
2000-04-25 |
Hokuriku Seiyaku Co Ltd |
1h-imidazopyridine derivative
|
EP1129089B1
(en)
|
1998-11-10 |
2005-12-28 |
Merck & Co., Inc. |
Spiro-indolines as y5 receptor antagonists
|
US6407120B1
(en)
|
1999-02-18 |
2002-06-18 |
Pfizer Inc. |
Neuropeptide Y antagonists
|
EP1184373A4
(en)
|
1999-04-20 |
2004-10-20 |
Meiji Seika Kaisha |
Tricyclic compounds
|
EP1249233B9
(en)
|
1999-11-26 |
2009-08-05 |
Shionogi & Co., Ltd. |
Npyy5 antagonists
|
BR0112409A
(en)
|
2000-07-13 |
2003-07-22 |
Lilly Co Eli |
Adrenergic beta3 agonists
|
WO2002022603A1
(en)
|
2000-09-15 |
2002-03-21 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
CA2403307A1
(en)
|
2001-10-23 |
2003-04-23 |
Neurogen Corporation |
Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
|
WO2003051397A1
(en)
*
|
2001-12-17 |
2003-06-26 |
Merck & Co., Inc. |
Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia
|
PE20040167A1
(en)
*
|
2002-03-28 |
2004-05-26 |
Novartis Ag |
SULPHAMIC ACID AMIDES
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
JP2006522109A
(en)
*
|
2003-03-31 |
2006-09-28 |
大正製薬株式会社 |
Novel quinazoline derivatives and therapeutic methods related to their use
|
JP2004315511A
(en)
*
|
2003-03-31 |
2004-11-11 |
Taisho Pharmaceut Co Ltd |
Mch receptor antagonist
|
US7371871B2
(en)
|
2003-05-05 |
2008-05-13 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
ES2228267B1
(en)
*
|
2003-07-30 |
2006-07-01 |
Laboratorios Del Dr. Esteve, S.A. |
COMBINATION OF ACTIVE SUBSTANCES CONTAINING AT LEAST ONE COMPOUND WITH AFFINITY FOR THE NEUROPEPTIDE RECEIVER AND (NPY) AND AT LEAST ONE COMPOUND WITH AFFINITY FOR THE RECEIVER 5-HT6.
|
EP1669350B1
(en)
|
2003-09-22 |
2012-02-29 |
Msd K.K. |
Piperidine derivatives
|
CA2542220A1
(en)
|
2003-10-22 |
2005-05-06 |
Eli Lilly And Company |
Novel mch receptor antagonists
|
NZ546887A
(en)
|
2003-11-03 |
2009-04-30 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
JP4996926B2
(en)
|
2004-02-05 |
2012-08-08 |
プロビオドルグ エージー |
Novel inhibitors of glutaminyl cyclase
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
DE602005013811D1
(en)
|
2004-11-01 |
2009-05-20 |
Amylin Pharmaceuticals Inc |
TREATMENT OF FAT AND HEALTHY DISEASES
|
CA2592900A1
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
JP5140577B2
(en)
*
|
2005-03-31 |
2013-02-06 |
タケダ カリフォルニア インコーポレイテッド |
Hydroxysteroid dehydrogenase inhibitor
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
US8138206B2
(en)
|
2005-05-30 |
2012-03-20 |
Msd. K.K. |
Piperidine derivative
|
CA2618112A1
(en)
|
2005-08-10 |
2007-02-15 |
Banyu Pharmaceutical Co., Ltd. |
Pyridone compound
|
EP1922336B1
(en)
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
BRPI0614649A2
(en)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
hybrid polypeptides with selectable properties
|
US7875633B2
(en)
|
2005-08-24 |
2011-01-25 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
EP1939194A4
(en)
|
2005-09-07 |
2010-12-08 |
Banyu Pharma Co Ltd |
Bicyclic aromatic substituted pyridone derivative
|
KR20080048502A
(en)
|
2005-09-29 |
2008-06-02 |
머크 앤드 캄파니 인코포레이티드 |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
CN101291662A
(en)
|
2005-10-21 |
2008-10-22 |
诺瓦提斯公司 |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
CA2627139A1
(en)
|
2005-10-27 |
2007-05-03 |
Banyu Pharmaceutical Co., Ltd. |
Novel benzoxathiin derivative
|
EP1953165B1
(en)
|
2005-11-10 |
2012-02-01 |
Msd K.K. |
Aza-substituted spiro derivative
|
EP2056828A4
(en)
*
|
2006-08-21 |
2010-06-23 |
Merck Sharp & Dohme |
Sulfonylated piperazines as cannabinoid-1 receptor modulators
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
AU2007301126A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
JP5379692B2
(en)
|
2006-11-09 |
2013-12-25 |
プロビオドルグ エージー |
3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
|
US9126987B2
(en)
|
2006-11-30 |
2015-09-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
CN101668525A
(en)
|
2007-03-01 |
2010-03-10 |
前体生物药物股份公司 |
New use of glutaminyl cyclase inhibitors
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
US9656991B2
(en)
|
2007-04-18 |
2017-05-23 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
CA3089569C
(en)
|
2007-06-04 |
2023-12-05 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US20110015181A1
(en)
|
2008-03-06 |
2011-01-20 |
Makoto Ando |
Alkylaminopyridine derivative
|
CA2717384A1
(en)
|
2008-03-28 |
2009-10-01 |
Banyu Pharmaceutical Co., Ltd. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2301936A1
(en)
|
2008-06-19 |
2011-03-30 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diarylketoxime derivative
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
AU2009277736A1
(en)
|
2008-07-30 |
2010-02-04 |
Banyu Pharmaceutical Co., Ltd. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
JP5575137B2
(en)
|
2008-10-22 |
2014-08-20 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Novel cyclic benzimidazole derivatives useful as antidiabetic agents
|
JP5635991B2
(en)
|
2008-10-30 |
2014-12-03 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonist
|
CA2741672A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
AU2010294214B2
(en)
|
2009-09-11 |
2015-05-07 |
Vivoryon Therapeutics N.V. |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
ES2586231T3
(en)
|
2010-03-03 |
2016-10-13 |
Probiodrug Ag |
Glutaminyl cyclase inhibitors
|
DK2545047T3
(en)
|
2010-03-10 |
2014-07-28 |
Probiodrug Ag |
Heterocyclic Inhibitors of Glutaminyl Cyclase (QC, EC 2.3.2.5)
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
AU2011245499B2
(en)
|
2010-04-30 |
2014-09-25 |
Merck Sharp & Dohme Corp. |
Novel beta 3 adrenergic receptor agonists
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
JP5728099B2
(en)
|
2011-02-25 |
2015-06-03 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents
|
EP2686313B1
(en)
|
2011-03-16 |
2016-02-03 |
Probiodrug AG |
Benzimidazole derivatives as inhibitors of glutaminyl cyclase
|
AR088352A1
(en)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
|
US9452990B2
(en)
|
2012-06-20 |
2016-09-27 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
RU2015106909A
(en)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
ANTI-DIABETIC TRICYCLIC COMPOUNDS
|
US9840512B2
(en)
|
2013-02-22 |
2017-12-12 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
JP2016514670A
(en)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
Guanylate cyclase receptor agonists in combination with other drugs
|
PL3004138T3
(en)
|
2013-06-05 |
2024-07-29 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
MX2017002610A
(en)
|
2014-08-29 |
2017-10-11 |
Tes Pharma S R L |
INHIBITORS OF A-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE.
|
MX2018016046A
(en)
|
2016-06-27 |
2019-05-02 |
Achillion Pharmaceuticals Inc |
Quinazoline and indole compounds to treat medical disorders.
|
BR112019007543A2
(en)
|
2016-10-14 |
2019-07-02 |
Tes Pharma S R L |
alpha-amino-beta-carboximuconic acid inhibitors semialdehyde decarboxylase
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
PL3461819T3
(en)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
WO2020104456A1
(en)
|
2018-11-20 |
2020-05-28 |
Tes Pharma S.R.L |
INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
US20230018413A1
(en)
|
2019-08-08 |
2023-01-19 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
BR112023002957A2
(en)
|
2020-08-18 |
2023-04-04 |
Merck Sharp & Dohme Llc |
COMPOUND, PHARMACEUTICAL COMPOSITION, AND, METHODS FOR TREATING NARCOLEPSY AND FOR TREATING HYPERSONIA IN A MAMMAL SUBJECT
|